Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2023-03-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2022年度社会责任报告
Regulatory Filings
2023-03-27 Chinese
天士力独立董事关于第八届董事会第18次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a pre-approval opinion from independent directors regarding matters to be submitted to the 18th meeting of the 8th board of directors. It includes opinions on related party transactions and the reappointment of an accounting firm for the 2023 fiscal year. The document is short (712 characters) and does not contain actual financial statements or detailed audit results. It is a governance-related document reflecting board-level approvals and opinions, not a full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board-related decisions and management matters.
2023-03-27 Chinese
天士力关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of TianShiLi Pharmaceutical Group Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and proxy authorization form. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3275 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2023-03-27 Chinese
天士力关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Tianjin Tasly Zhijiao Pharmaceutical Co., a subsidiary of Tasly Pharmaceutical Group Co., Ltd., regarding the receipt of a drug registration certificate for a pharmaceutical product (injection of Nicorandil). It details the drug's registration, approval by the National Medical Products Administration, product specifications, and potential market impact. The document is an announcement of a regulatory approval event rather than a financial report, management change, or earnings release. It does not contain financial statements or detailed financial data. The document length is short (1327 characters), and it is clearly an announcement of a regulatory event related to product registration. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-17 Chinese
天士力关于参与设立生物医药股权投资合伙企业（有限合伙）暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding its participation in establishing a biopharmaceutical equity investment partnership and related party transactions. It details the investment amount, partners, terms of the partnership, risk disclosures, and approvals by the board and supervisory committee. The document is a formal public announcement of a corporate transaction involving related parties and investment in a fund structure. It does not contain financial statements, audit opinions, earnings data, or detailed management discussion of financial results. It is not a report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a proxy solicitation, voting results, or a regulatory certification. The content fits the category of a Capital/Financing Update (CAP) because it announces a new investment and related party transaction involving capital commitment and fund formation. The document length (6319 characters) and detailed disclosure support this classification with high confidence.
2023-02-10 Chinese
天士力独立董事关于第八届董事会第17次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting agenda item related to a related-party transaction. It references legal and regulatory frameworks and confirms the fairness and legality of the transaction. The document is short (713 characters) and focuses on board-level approval and independent director opinion rather than financial data or report publication. It is not an annual or interim report, audit report, or earnings release. It is not a general regulatory filing or announcement but specifically relates to board/management information about a transaction and board meeting decisions. Therefore, the best fit is Board/Management Information (MANG).
2023-02-10 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.